Barclays
CRBP icon

Barclays’s Corbus Pharmaceuticals CRBP Stock Holding History

Barclays’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$195K Buy
20,782
+6,024
+41% +$50.7K ﹤0.01% 3699
2025
Q4 		$120K Buy
14,758
+10,874
+280% +$134K ﹤0.01% 4525
2025
Q3 		$49.1K Buy
3,884
+3,293
+557% +$31.3K ﹤0.01% 4777
2025
Q2 		$4.08K Sell
591
-11,879
-95% -$86.3K ﹤0.01% 4990
2025
Q1 		$66.2K Sell
12,470
-5,686
-31% -$50.2K ﹤0.01% 4534
2024
Q4 		$214K Sell
18,156
-20,306
-53% -$341K ﹤0.01% 4277
2024
Q3 		$793K Sell
38,462
-53,266
-58% -$2.73M ﹤0.01% 3509
2024
Q2 		$4.15M Sell
91,728
-93,420
-50% -$3.93M ﹤0.01% 1647
2024
Q1 		$7.27M Buy
+185,148
New +$4.57M ﹤0.01% 1605
2022
Q1 		– Sell
-1,700
Closed -$31K – 5045
2021
Q4 		$31K Sell
1,700
-487
-22% -$13.2K ﹤0.01% 3905
2021
Q3 		$68K Buy
2,187
+154
+8% +$6.07K ﹤0.01% 4033
2021
Q2 		$111K Sell
2,033
-108
-5% -$5.99K ﹤0.01% 3807
2021
Q1 		$126K Buy
+2,141
New +$141K ﹤0.01% 3908
2020
Q4 		– Sell
-321
Closed -$17K – 4922
2020
Q3 		$17K Sell
321
-895
-74% -$162K ﹤0.01% 4919
2020
Q2 		$305K Buy
1,216
+1,213
+40,433% +$245K ﹤0.01% 3736
2020
Q1 		$0 Sell
3
-1
-25% -$169 ﹤0.01% 6176
2019
Q4 		$0 Sell
4
-1,220
-100% -$180K ﹤0.01% 6403
2019
Q3 		$179K Sell
1,224
-1,176
-49% -$205K ﹤0.01% 5049
2019
Q2 		$499K Buy
2,400
+290
+14% +$62.1K ﹤0.01% 4321
2019
Q1 		$440K Buy
2,110
+1,809
+601% +$399K ﹤0.01% 4234
2018
Q4 		$52K Buy
301
+296
+5,920% +$59.1K ﹤0.01% 5454
2018
Q3 		$1K Sell
5
-358
-99% -$57.9K ﹤0.01% 7008
2018
Q2 		$54K Sell
363
-580
-62% -$105K ﹤0.01% 5594
2018
Q1 		$172K Buy
943
+663
+237% +$149K ﹤0.01% 4959
2017
Q4 		$60K Sell
280
-653
-70% -$140K ﹤0.01% 5639
2017
Q3 		$200K Buy
933
+532
+133% +$104K ﹤0.01% 4425
2017
Q2 		$76K Sell
401
-992
-71% -$195K ﹤0.01% 5098
2017
Q1 		$345K Sell
1,393
-400
-22% -$98.2K ﹤0.01% 3774
2016
Q4 		$454K Buy
+1,793
New +$411K ﹤0.01% 3458

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Barclays's CRBP Position: Q1 2026 in Review

Barclays increased its Corbus Pharmaceuticals (CRBP) stake by 41% in Q1 2026, buying an estimated $50.7K and bringing the position to 20,782 shares worth $195K. The position accounts for ﹤0.01% of the portfolio, ranked #3699.

Barclays first reported a position in CRBP in Q4 2016 and has held it in 29 quarters since. The position peaked at $7.27M in Q1 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Barclays held 20,782 shares of Corbus Pharmaceuticals worth $195K as of Q1 2026.
  • Barclays bought 6,024 Corbus Pharmaceuticals shares in Q1 2026, an estimated $50.7K.
  • Corbus Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3699 holding.
  • Barclays first reported a position in Corbus Pharmaceuticals in Q4 2016 and has held it in 29 quarters since.
  • Barclays's Corbus Pharmaceuticals position peaked at $7.27M in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.